What are BTK inhibitors?
BTK inhibitors are targeted cancer medicines taken as tablets or capsules. They block an enzyme called Bruton’s tyrosine kinase (BTK), which B cells rely on to survive and multiply. Many B-cell cancers, including chronic lymphocytic leukaemia (CLL), mantle cell lymphoma and Waldenstrom macroglobulinaemia, depend heavily on signals that pass through BTK.
The first BTK inhibitor, ibrutinib, was approved in 2013. Since then, more selective drugs such as acalabrutinib and zanubrutinib, and the non-covalent inhibitor pirtobrutinib, have been developed. These newer drugs aim to keep the benefits while causing fewer side effects, particularly heart problems.
BTK inhibitors have changed CLL treatment profoundly. For many people, a daily tablet has replaced chemotherapy, giving long-lasting control of the disease with a manageable side effect profile.
A brief history
BTK was identified in 1993 as the gene behind X-linked agammaglobulinaemia, a rare inherited condition in which boys cannot make B cells or antibodies. This showed how essential BTK is for B-cell development. Researchers later realised that blocking it might stop B-cell cancers. Ibrutinib’s success in early trials in CLL and mantle cell lymphoma led to rapid approvals, and second-generation drugs followed within a few years.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Targeted therapy (kinase inhibitors) |
| Main uses | Chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenstrom macroglobulinaemia, marginal zone lymphoma |
| How it is given | Tablets or capsules taken once or twice a day at home |
| Course length | Usually continuous while it works; sometimes for a fixed period in combination with venetoclax |
| Common side effects | Bruising, diarrhoea, joint and muscle aches, headache, infections |
| Important risks | Bleeding, irregular heartbeat (atrial fibrillation), high blood pressure |
| Monitoring | Blood counts, blood pressure and heart rhythm checks |
2. How it works
The B-cell receptor pathway
B cells carry receptors on their surface that recognise specific targets. When the receptor is stimulated, it sends a chain of signals inside the cell, and BTK is a key link in this chain. In many B-cell cancers, this pathway is constantly active, keeping the cancer cells alive and helping them home to lymph nodes and bone marrow, where they are protected.
Effects of blocking BTK
| Effect | What happens |
|---|---|
| Survival signals switched off | Cancer cells die gradually |
| Cells leave protective sites | Cells move out of lymph nodes into the blood |
| Reduced growth | Fewer new cancer cells are made |
Lymphocytosis: a rise that is not a bad sign
When people start a BTK inhibitor, the lymphocyte count in the blood often rises for weeks or months, even while lymph nodes shrink. This happens because cancer cells are pushed out of lymph nodes into the bloodstream, where they eventually die. It is an expected effect and does not mean that the treatment is failing.
Types of BTK inhibitors
| Type | Drugs | Features |
|---|---|---|
| First-generation covalent | Ibrutinib | Also blocks other kinases, causing more off-target side effects |
| Second-generation covalent | Acalabrutinib, zanubrutinib | More selective; fewer heart side effects |
| Non-covalent | Pirtobrutinib | Works even when the usual BTK binding site has mutated |
Covalent inhibitors form a permanent bond with a specific part of BTK called C481. Mutations at this site are a common cause of resistance, which is why non-covalent drugs were developed.
3. Who it is for
Conditions treated
| Condition | Role of BTK inhibitors |
|---|---|
| Chronic lymphocytic leukaemia | First treatment and at relapse; especially valuable for high-risk genetics such as TP53 mutation or 17p deletion |
| Mantle cell lymphoma | Relapsed disease, and increasingly in first-line treatment |
| Waldenstrom macroglobulinaemia | First-line or relapsed disease |
| Marginal zone lymphoma | After previous treatment |
Why genetics matter in CLL
Doctors test CLL cells for changes that predict how the disease will behave. A TP53 mutation or 17p deletion means the cancer is less likely to respond to chemotherapy, but BTK inhibitors still work well. Unmutated IGHV status also points towards a more active disease that tends to respond better to targeted drugs than to chemotherapy. These results help decide which treatment to start with.
Who may need extra care
| Situation | Consideration |
|---|---|
| Heart rhythm problems | Atrial fibrillation risk; more selective BTK inhibitors may be preferred |
| High blood pressure | Needs monitoring and treatment |
| Taking blood thinners | Increased bleeding risk; warfarin is usually avoided |
| Planned surgery | Treatment is paused before and after operations |
| Liver disease | Dose changes may be needed |
4. Before treatment
| Step | Why it is done |
|---|---|
| Diagnosis and staging | Blood tests, scans or bone marrow tests |
| Genetic tests on the cancer | TP53, 17p deletion and IGHV status help choose treatment |
| Heart assessment | ECG and blood pressure check |
| Medicines review | Blood thinners and drugs that change BTK inhibitor levels |
| Hepatitis B test | Risk of reactivation |
| Vaccinations | Ideally given before starting treatment |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Starting tablets | At home, at the same time each day |
| 2. Early checks | Blood tests and review every few weeks |
| 3. Lymphocyte rise | Common in the first months, especially in CLL |
| 4. Response | Lymph nodes and spleen shrink; blood counts improve |
| 5. Ongoing monitoring | Visits every 2-3 months once stable |
| 6. Long-term treatment | Continued while it works and is tolerated |
| 7. Change of treatment | If side effects are troublesome, switching to another BTK inhibitor is often possible |
Fixed-duration treatment
Some people with CLL now receive a BTK inhibitor combined with venetoclax for a fixed period, usually around one to two years, instead of indefinitely. This allows time off treatment if the response is deep. Your team will explain whether continuous or fixed-duration treatment suits you better.
6. Side effects and risks
| Side effect | Notes |
|---|---|
| Bruising and minor bleeding | Common; BTK affects platelet function |
| Major bleeding | Uncommon; higher risk with blood thinners |
| Atrial fibrillation | Irregular heartbeat; more common with ibrutinib |
| High blood pressure | Can develop over months or years |
| Diarrhoea | Usually mild and early |
| Joint and muscle aches | Common, especially with ibrutinib |
| Headache | Common with acalabrutinib in the first weeks; caffeine may help |
| Infections | Chest and other infections are more common |
| Low blood counts | Usually mild |
| Rash and nail changes | Brittle nails are fairly common |
In the ALPINE trial, zanubrutinib was both better tolerated and more effective than ibrutinib (Brown et al., 2023). In the mantle cell lymphoma trial of ibrutinib, the most common side effects were mild or moderate diarrhoea, tiredness and nausea (Wang et al., 2013).
7. Results and outlook
| Study | Main finding |
|---|---|
| RESONATE-2, untreated CLL in people 65 or older (269 people) | Ibrutinib reduced the risk of progression or death by 84% compared with chlorambucil, and 2-year survival was 98% versus 85% (Burger et al., 2015) |
| Alliance A041202, untreated CLL in older adults | Two-year progression-free survival was 87% with ibrutinib compared with 74% with bendamustine plus rituximab (Woyach et al., 2018) |
| ALPINE, relapsed CLL (652 people) | Zanubrutinib controlled CLL better than ibrutinib, with 2-year progression-free survival of 78% versus 66% (Brown et al., 2023) |
| Ibrutinib in relapsed mantle cell lymphoma (111 people) | About two thirds responded, including about one in five with complete responses (Wang et al., 2013) |
What the evidence means
For most people with CLL, BTK inhibitors control the disease for many years. People with high-risk genetic features, who used to do poorly with chemotherapy, benefit particularly. The choice between drugs now often depends on side effects, other health conditions and convenience.
8. Recovery and aftercare
Living with daily tablets
| Tip | Why |
|---|---|
| Take your tablets at the same time each day | Keeps steady levels |
| Tell all health professionals you take a BTK inhibitor | Especially dentists and surgeons |
| Check your blood pressure regularly | Rises are common |
| Report palpitations, dizziness or breathlessness | Possible atrial fibrillation |
| Avoid grapefruit, Seville oranges and St John’s wort | They change drug levels |
| Seek help for signs of infection | Fever or cough may need prompt treatment |
Before surgery or dental work
Because BTK inhibitors affect bleeding, they are usually paused for a few days before and after surgery, depending on the size of the procedure. Do not stop or restart on your own; your haematology team will advise on timing.
Managing aches and bruising
Joint and muscle aches often ease after the first few months. Gentle stretching, warm baths and simple painkillers such as paracetamol can help; check before taking anti-inflammatory drugs. Bruising usually needs no treatment, but tell your team about nosebleeds that will not stop, blood in urine or stools, or large unexplained bruises.
Vaccinations
People with CLL have weakened immunity, and BTK inhibitors can reduce responses to vaccines. Inactivated vaccines, such as flu, pneumococcal and COVID-19 vaccines, are still recommended. Live vaccines are usually avoided.
Atrial fibrillation
Atrial fibrillation is an irregular, often fast, heartbeat. It may cause palpitations, breathlessness or dizziness, but sometimes causes no symptoms and is found on a routine check. If it develops, your team may treat it with heart medicines, change the BTK inhibitor or pause treatment. Some blood thinners used for atrial fibrillation interact with BTK inhibitors, so heart and haematology specialists usually plan treatment together.
Coping with long-term treatment
Taking a tablet every day for years can feel like a constant reminder of the illness. At the same time, many people find comfort in the stability it brings. Joining a CLL or lymphoma support group can help you connect with others in a similar position and share practical tips.
Long-term life
Many people take BTK inhibitors for years while working, travelling and enjoying normal activities. Regular follow-up focuses on blood counts, heart health, infections and skin checks, as people with CLL have a higher risk of skin cancers.
If resistance develops
If the disease progresses, tests can look for mutations in BTK or related genes. Options may include switching to pirtobrutinib, venetoclax-based treatment, CAR-T cell therapy in selected cases, or clinical trials.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Venetoclax with obinutuzumab | Fixed-duration treatment for CLL |
| Chemoimmunotherapy | Selected younger people with favourable CLL genetics, less often now |
| Active monitoring | Early CLL without symptoms |
| CAR-T cell therapy | Relapsed mantle cell lymphoma and some CLL |
| Allogeneic stem cell transplant | Rarely, for high-risk disease in fit people |
| Clinical trials | New drugs, including BTK degraders |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is this chemotherapy? | No, it is a targeted tablet |
| Will I lose my hair? | Hair loss is uncommon; hair and nails may become more brittle |
| Why has my lymphocyte count gone up? | This is expected early on and is usually not a concern |
| Can I take aspirin or ibuprofen? | Check first; they can increase bleeding risk |
| What if I miss a dose? | Take it the same day if you remember; do not double up |
| Do I need to stop before dental work? | Ask your team; it depends on the procedure |
| Can I drink alcohol? | Moderate amounts are usually fine, but check with your team |
| Can I travel? | Yes; carry enough tablets and details of your treatment |
| Will I take it forever? | Often for as long as it works; sometimes for a fixed period |
11. Questions to ask your care team
- Which BTK inhibitor do you recommend for me, and why?
- Should I have continuous or fixed-duration treatment?
- How will you monitor my heart and blood pressure?
- What should I do before surgery or dental work?
- Which vaccines should I have?
- What are the main side effects to report?
- What happens if the treatment stops working?
Resources
- Brown, J.R. et al. (2023) ‘Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia’, New England Journal of Medicine, 388(4), pp. 319-332.
- Burger, J.A. et al. (2015) ‘Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia’, New England Journal of Medicine, 373(25), pp. 2425-2437.
- Wang, M.L. et al. (2013) ‘Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma’, New England Journal of Medicine, 369(6), pp. 507-516.
- Woyach, J.A. et al. (2018) ‘Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL’, New England Journal of Medicine, 379(26), pp. 2517-2528.
- National Cancer Institute (2026) Chronic Lymphocytic Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Ibrutinib. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/ibrutinib (Accessed: October 2026).
Prepared by the editorial team, October 2026.